In 24 people with newly diagnosed glioblastoma, high-dose niacin plus standard care had an early progression-free signal

What the research found

Study (interim phase 1–2 cancer trial; controlled-release niacin with chemotherapy and radiotherapy). ScienceDaily carried the University of Calgary account on 4 October 2026. Gloria Roldan Urgoiti, Wee Yong, and colleagues report in the Journal of Neuro-Oncology (2025; 176(1); doi 10.1007/s11060-025-05351-z). The idea came from mouse work in which niacin lengthened survival. In people, the team set a stop rule if six-month progression-free survival did not beat older studies by at least 20 percent. In the first 24 patients, 82 percent were progression-free at six months, which the researchers describe as a 28 percent increase versus those earlier studies. They plan to enroll 48 and to finish analysis in late 2026 or early 2027. Ages for the 24 are not given. The release says high-dose niacin can be toxic and is being given only under medical monitoring. Store-shelf vitamin B3 is not this protocol, and the result is preliminary. Educational notes. This is not medical advice and not a substitute for prescribed cancer treatment.

Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.

Read the original at University of Calgary / Journal of Neuro-Oncology